Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

Investigations of apolipoprotein E (APOE) gene, the major genetic risk modifier for
Alzheimer's disease (AD), have yielded significant insights into the pathogenic mechanism …

Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …

The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and
represents one of the earliest pathomechanistic alterations throughout the AD continuum …

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the
Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for …

The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of early-
onset dementia. The diagnosis of bvFTD remains challenging because of the limited …

A hallmark of neurodegenerative proteinopathies is the formation of misfolded protein
aggregates that cause cellular toxicity and contribute to cellular proteostatic collapse …

Introduction We studied whether fully automated Elecsys cerebrospinal fluid (CSF)
immunoassay results were concordant with positron emission tomography (PET) and …